IL6 and neoplasm: The results showed that ATL-1 could reduce the production of extracellular vesicles (EVs) and IL-6 secretion by regulating the STAT3/PKM2/SNAP23 pathway, which inhibited aerobic glycolysis and suppressed the ability of tumor cells to induce muscle atrophy, thus alleviating malignant disease.